Healthcare, Vol. 11, Pages 924: A Case Series on Pain Accompanying Photoimmunotherapy for Head and Neck Cancer

Healthcare, Vol. 11, Pages 924: A Case Series on Pain Accompanying Photoimmunotherapy for Head and Neck Cancer

Healthcare doi: 10.3390/healthcare11060924

Authors: Yuma Shibutani Haruna Sato Shinya Suzuki Takeshi Shinozaki Hayato Kamata Kazuki Sugisaki Atushi Kawanobe Shinya Uozumi Toshikatsu Kawasaki Ryuichi Hayashi

One of the most severe side effects of photoimmunotherapy (PIT) for head and neck cancer is pain. As there are presently no detailed reports on pain and pain management in PIT, we conducted a retrospective case series study. We conducted a retrospective study of five patients who had received PIT at the National Cancer Center Hospital East between January 2021 and June 2022 using medical chart data. All patients experienced pain, evidenced by an increased numerical rating scale (NRS) after PIT, regardless of the illumination method. The daily change in mean NRS rating shows that the pain was highest on the day of PIT, with ratings of 6.8 and 7.8 for the frontal and cylindrical diffuser methods, respectively; it dropped the following day quickly. Four of the five patients received fentanyl injections for postoperative pain management beginning on postoperative day (POD) 0. All patients who underwent therapy using a cylindrical diffuser required postoperative pain management with opioid drugs. Pain after PIT tended to be most intense immediately after or one hour after illumination and declined the following day, suggesting the need to have a pain relief plan in place in advance.